FinQuota.com
Home
News
Screener
Backtests
Tools
Compare Stocks
Dividend Calculator
Options Calculator
NYSE Holidays
NASDAQ Holidays
Earnings Calendar
Widgets
Filter
Dividend Stocks
US Dividend Stocks
Monthly Dividend Stocks
Annual Dividend Stocks
Quarterly Dividend Stocks
Semi-Annual Dividend Stocks
Best Penny Stocks
Undervalued Stocks
New Stocks
Uptrend Stocks
Uptrend Penny Stocks
Blue Chip
Blue Chip Stocks With High Dividends
Blue Chip Under $10
Blue Chip Under $20
Blue Chip Under $50
Undervalued Blue Chip Stocks
By Cap
Best Small Cap
Best Micro Cap
Best Mid Cap
Best Large Cap
By Sector
Oil Stocks
Energy Stocks
Technology Stocks
AI Stocks
Pharma Stocks
Financial Stocks
By Price
Under $200
Under $100
Under $50
Under $20
Under $10
Under $5
Under $1
By 52 Week Range
Best 52 Week Low
Best 52 Week Nasdaq Low
Best 52 Week NYSE Low
Best 52 Week Low Penny
Best 52 Week Low Blue Chip
Best 52 Week High
Best 52 Week Nasdaq High
Best 52 Week NYSE High
Best 52 Week High Penny
By Exchange
Best Nasdaq Stocks
Best NYSE Stocks
By Insider Activity
Insider Buying
Insider Selling
By Indicator
MACD Crossed Above Signal Line
MACD Crossed Above Zero
RSI Above 90
RSI Above 80
RSI Above 70
RSI Above 50
RSI Below 50
RSI Below 30
RSI Below 20
RSI Below 10
By P/E Ratio
Tech Stocks with Low PE
PE Ratio Less Than 1
PE Ratio Less Than 10
PE Ratio Less Than 15
US stocks With Low PE
Low PE & High Dividends
Low PE & High EPS
Large Cap & Lowest PE
Learning
Books
Trading Platforms
Blog
Forum
Auto (Default)
Light mode
Dark
Sign In
Sign Up
FinQuota.com
Home
Account
Sign In
Sign Up
News
Screener
Backtests
Tools
Compare Stocks
Dividend Calculator
Options Calculator
NYSE Holidays
NASDAQ Holidays
Earnings Calendar
Widgets
Filter
Dividend Stocks
US Dividend Stocks
Monthly Dividend Stocks
Annual Dividend Stocks
Quarterly Dividend Stocks
Semi-Annual Dividend Stocks
Best Penny Stocks
Undervalued Stocks
New Stocks
Uptrend Stocks
Uptrend Penny Stocks
Blue Chip
Blue Chip Stocks With High Dividends
Blue Chip Under $10
Blue Chip Under $20
Blue Chip Under $50
Undervalued Blue Chip Stocks
By Cap
Best Small Cap
Best Micro Cap
Best Mid Cap
Best Large Cap
By Sector
Oil Stocks
Energy Stocks
Technology Stocks
AI Stocks
Pharma Stocks
Financial Stocks
By Price
Under $200
Under $100
Under $50
Under $20
Under $10
Under $5
Under $1
By 52 Week Range
Best 52 Week Low
Best 52 Week Nasdaq Low
Best 52 Week NYSE Low
Best 52 Week Low Penny
Best 52 Week Low Blue Chip
UBest 52 Week High
Best 52 Week Nasdaq High
Best 52 Week NYSE High
Best 52 Week High Penny
By Exchange
Nasdaq Stocks
NYSE Stocks
By Insider Activity
Insider Buying
Insider Selling
By Indicator
MACD Crossed Above Signal Line
MACD Crossed Above Zero
RSI Above 90
RSI Above 80
RSI Above 70
RSI Above 50
RSI Below 50
RSI Below 30
RSI Below 20
RSI Below 10
By P/E Ratio
Tech Stocks with Low PE
PE Ratio Less Than 1
PE Ratio Less Than 10
PE Ratio Less Than 15
US stocks With Low PE
Low PE & High Dividends
Low PE & High EPS
Large Cap & Lowest PE
Learning
Books
Trading Platforms
Blog
Forum
Search Ticker
Home
ENTO
ENTO News
Latest Entero Therapeutics Inc. Common Stock (ENTO) News on January 19, 2025
ENTO
GlobeNewswire
2 months ago
Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum
ENTO
GlobeNewswire
2 months ago
Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company
ENTO
GlobeNewswire
4 months ago
Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings
ENTO
GlobeNewswire
5 months ago
Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q
ENTO
GlobeNewswire
6 months ago
Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program
ENTO
GlobeNewswire
6 months ago
Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds
ENTO
GlobeNewswire
6 months ago
Entero Therapeutics Announces Abstract on Celiac Disease Research Accepted for Presentation at the 20th International Celiac Disease Symposium
ENTO
GlobeNewswire
7 months ago
Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease
Share on Social Networks:
